Skip to content
10-Q

Quarterly Report

Renalytix plc RENXF RNLXY

0000950170-24-128687

← back to feed
Filed
Nov 19, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Nov 7, 2024 331.21M sh
Shares Diluted Q1 2025 · Sep 30, 2024 105.7M sh
Shares Diluted Q1 2025 · Sep 30, 2023 94.77M sh
Operating Cash Flow Q1 2025 · Sep 30, 2024 −$3.84M
Operating Cash Flow Q1 2025 · Sep 30, 2023 −$9.5M
Cash And Equivalents Q1 2025 · Sep 30, 2024 $909K
Cash And Equivalents Q1 2025 · Jun 30, 2024 $4.68M
Stockholders Equity Q1 2025 · Sep 30, 2024 −$11.32M
Stockholders Equity Q1 2025 · Jun 30, 2024 −$7.85M
Stockholders Equity Q1 2025 · Sep 30, 2023 −$1.49M
Stockholders Equity Q1 2025 · Jun 30, 2023 $6.97M
Current Liabilities Q1 2025 · Sep 30, 2024 $12.01M
Current Liabilities Q1 2025 · Jun 30, 2024 $11.5M
Total Liabilities Q1 2025 · Sep 30, 2024 $16.11M
Total Liabilities Q1 2025 · Jun 30, 2024 $15.83M
Current Assets Q1 2025 · Sep 30, 2024 $2.88M
Current Assets Q1 2025 · Jun 30, 2024 $6.12M
Total Assets Q1 2025 · Sep 30, 2024 $4.79M
Total Assets Q1 2025 · Jun 30, 2024 $7.97M
Eps Diluted Q1 2025 · Sep 30, 2024 −$0.04
Eps Diluted Q1 2025 · Sep 30, 2023 −$0.11
Eps Basic Q1 2025 · Sep 30, 2024 −$0.04
Eps Basic Q1 2025 · Sep 30, 2023 −$0.11
Sga Expense Q1 2025 · Sep 30, 2024 $3.27M
Sga Expense Q1 2025 · Sep 30, 2023 $6.06M
Net Income Q1 2025 · Sep 30, 2024 −$4.73M
Net Income Q1 2025 · Sep 30, 2023 −$10.15M
Operating Income Q1 2025 · Sep 30, 2024 −$4.09M
Operating Income Q1 2025 · Sep 30, 2023 −$8.89M
Gross Profit Q1 2025 · Sep 30, 2024 $100K
Gross Profit Q1 2025 · Sep 30, 2023 −$43K
Cost Of Revenue Q1 2025 · Sep 30, 2024 $422K
Cost Of Revenue Q1 2025 · Sep 30, 2023 $502K